Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | ACE | P12821 | 4/20 | 0.68 |
| ▸ | ITGB2 | P05107 | 6/20 | 0.67 |
| ▸ | ICAM1 | P05362 | 6/20 | 0.67 |
| ▸ | ITGAL | P20701 | 6/20 | 0.67 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.66 |
| ▸ | FPR2 | P25090 | 1/20 | 0.66 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | ECE1 | P42892 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29987387 | 0.90 | ALOX15 (0.70) | ALOX15ACEITGB2ICAM1ITGAL | |
| SCHEMBL1994981 | 0.90 | ALOX15 (0.70) | ALOX15ACEITGB2ICAM1ITGAL | |
| SCHEMBL13278205 | 0.90 | ALOX15 (0.70) | ALOX15ACEITGB2ICAM1ITGAL | |
| SCHEMBL30936746 | 0.90 | ALOX15 (0.70) | ALOX15ACEITGB2ICAM1ITGAL | |
| SCHEMBL3728145 | 0.90 | ALOX15 (0.70) | ALOX15ACEITGB2ICAM1ITGAL | |
| SCHEMBL1994982 | 0.90 | ALOX15 (0.70) | ALOX15ACEITGB2ICAM1ITGAL | |
| SCHEMBL11495534 | 0.88 | ACE (0.71) | ALOX15ACEITGB2ICAM1ITGAL | |
| SCHEMBL7745569 | 0.88 | ALOX15 (0.68) | ALOX15ACEITGB2ICAM1ITGAL | |
| SCHEMBL1407978 | 0.88 | ALOX15 (0.68) | ALOX15ACEITGB2ICAM1ITGAL | |
| SCHEMBL11495529 | 0.88 | ACE (0.71) | ALOX15ACEITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906058-B2 | 1,5-Benzothiazepines and their use as hypolipidaemics | ASTRAZENECA AB (SE) | 2005-06-14 | — | — | US | claimed |
| EP-1263747-B1 | 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS | ASTRAZENECA AB (SE) | 2004-11-24 | — | — | EP | claimed |
| US-20030166927-A1 | 1,5-Benzothiazepines and their use as hypolipidaemics | ALBIREO AB (SE) | 2003-09-04 | — | — | US | claimed |
| EP-1263747-A1 | 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | claimed |
| WO-2001066533-A1 | 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | claimed |
| US-6906058-B2 | 1,5-Benzothiazepines and their use as hypolipidaemics | ASTRAZENECA AB (SE) | 2005-06-14 | — | — | US | disclosed |
| EP-1263747-B1 | 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS | ASTRAZENECA AB (SE) | 2004-11-24 | — | — | EP | disclosed |
| US-20030166927-A1 | 1,5-Benzothiazepines and their use as hypolipidaemics | ALBIREO AB (SE) | 2003-09-04 | — | — | US | disclosed |
| EP-1263747-A1 | 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001066533-A1 | 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166927-A1 | 1,5-Benzothiazepines and their use as hypolipidaemics | SLC10A2, SLC10A1, LCAT | ALOX15 1095/4885ACE 1590/4885ITGB2 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.